November 24, 2026

Actinium Pharmaceuticals Announces SABCS 2026 Abstract Highlighting Broad Antitumor Activity of HER3-Targeted ATNM-400 Across Breast Cancer Subtypes and Treatment-Resistant Models

- ATNM-400 demonstrates preclinical antitumor activity across hormone receptor-positive, HER2-positive and triple-negative breast cancer models
- RADIANZ imaging trial is enrolling patients with breast cancer and other solid tumors including non-small cell lung, colorectal, pancreatic and ovarian cancers with results expected in the first half of 2027
- Following trastuzumab failure, ATNM-400 demonstrates greater tumor growth inhibition than the HER2 antibody-drug conjugate trastuzumab deruxtecan in a breast cancer model
- Increased HER3 expression in tamoxifen- and trastuzumab-resistant cells supports targeting a biologic driver of treatment resistance

NEW YORK, Nov. 24, 2026 /PRNewswire/ -- **Actinium Pharmaceuticals, Inc.** (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced the release of an abstract highlighting preclinical data demonstrating ATNM-400's broad antitumor activity across breast cancer subtypes and treatment-resistant models. The findings will be presented at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8–11, 2026, in San Antonio, Texas.

The presentation features ATNM-400, the Company's investigational, first-in-class Actinium-225 (^{225}Ac) antibody radioconjugate targeting HER3, a receptor implicated in tumor progression, survival signaling and treatment resistance. The study demonstrates activity across hormone receptor-positive, HER2-positive and triple-negative breast cancer models, including models resistant to established therapies, supporting further evaluation as monotherapy and in combination with standard-of-care treatments.

ATNM-400 demonstrated robust antitumor activity across trastuzumab-resistant, triple-negative and estrogen receptor-positive, HER2-negative breast cancer models. Following trastuzumab failure, ATNM-400 produced greater tumor growth inhibition than the HER2 antibody-drug conjugate trastuzumab deruxtecan. Treatment was well tolerated in the evaluated models, with no significant body weight loss.

HER3 expression increased in tamoxifen- and trastuzumab-resistant cells, supporting the rationale for targeting treatment-resistant disease. ATNM-400 retained cytotoxic activity in resistant cells and following prior standard-of-care exposure, and enhanced cytotoxicity when combined with tamoxifen or trastuzumab. Biodistribution studies demonstrated sustained tumor uptake with rapid normal-organ clearance.

These breast cancer findings expand the preclinical evidence supporting ATNM-400's pan-tumor potential, building on previously reported activity in prostate, non-small cell lung, colorectal and ovarian cancer models. They also support the rationale for RADIANZ, a PET imaging study of Zirconium-89-labeled barecetamab that is enrolling patients with breast cancer and other advanced solid tumors who have progressed on standard-of-care therapy. RADIANZ evaluates tumor uptake, retention and biodistribution to guide ATNM-400's clinical development beyond prostate cancer, with results expected in the first half of 2027.

"These findings strengthen the preclinical foundation for ATNM-400's pan-cancer potential and our strategy to address treatment resistance across major solid tumor indications," said Sandesh Seth, Actinium's Chairman and CEO. "HER3 is implicated in resistance to standard-of-care therapies, and the increased target expression observed in tamoxifen- and trastuzumab-resistant breast cancer cells reinforces the rationale for our approach. These preclinical results support further development of ATNM-400 across breast cancer subtypes, with greater tumor growth inhibition than trastuzumab deruxtecan observed after trastuzumab failure. With RADIANZ now enrolling patients with breast cancer and other solid tumors, we are evaluating HER3-targeted tumor uptake in patients to guide ATNM-400's development beyond prostate cancer and advance our pan-cancer strategy."

ATNM-400 SABCS 2026 Presentation Details

Abstract Title: ATNM-400, a First-in-Class Targeted Alpha Therapy Targeting a Driver of Tumor Biology and Treatment Resistance, Demonstrates Efficacy Across Therapy-Resistant Breast Cancer Subtypes

Abstract Number: 1626

Presentation Number: P2-12-17

Presentation Type: Poster presentation

Presentation Date & Time: Wednesday, December 9, 2026, 5:00–6:30 p.m. CST | San Antonio, Texas

Location: Exhibit Hall

About ATNM-400

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ^{89}Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ^{225}Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis' Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals' TLX591-Tx, Clarity Pharmaceuticals' ^{67}Cu-SAR-bisPSMA, Convergent Therapeutics' CONV01-α, AstraZeneca's AZD2265 (formerly FPI-2265), Curium's lutetium-177 zadavotide guraxetan (^{177}Lu-PSMA-I&T), ARTBIO's AB001 and AdvanCell's ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-

directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

About HER3

HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink's BNT326/YL202; Bristol Myers Squibb and SystImmune's EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck's patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets HER3, an antigen distinct from PSMA, and is in a first-in-human Phase 1/2a study in metastatic castration-resistant prostate cancer (mCRPC) and the RADIANZ pan-cancer study, with preclinical activity across mCRPC, NSCLC, breast, colorectal and ovarian cancers. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials,

actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investor Contact

Peter (PJ) Kelleher
LifeSci Advisors
pkelleher@lifesciadvisors.com
(617) 430-7579

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-sabcs-2026-abstract-highlighting-broad-antitumor-activity-of-her3-targeted-atnm-400-across-breast-cancer-subtypes-and-treatment-resistant-models-302948774.html

SOURCE Actinium Pharmaceuticals, Inc.